stockrow
Friday 6 November 2026
Export CBIO’s income statement to Excel — free account
Crescent Biopharma, Inc.
CBIO Healthcare Biotechnology
Crescent Biopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.8 million, up 108,340.0% from fiscal 2023.
- Revenue
- +1,038,900.0%
- EPS
- +85.0%
- Free cash flow
- −7.04%
Quarter to June 2026, against a year earlier
13.48
0.54
+4.17%
Follow CBIO
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 |
Piotroski F-Score |
— | — | 3 | 2 | — | — | — | — | — | 3 |
Altman Z-Score |
(0.06) | — | (2.99) | (2.63) | (3.25) | 3.96 | — | — | — | 5.53 |
P/S ratio |
688.83 | — | 960.87 | 852.55 | 63.89 | 16.88 | — | — | — | 3.80 |
Altman Z″-Score (non-manufacturers) |
4.59 | — | (27.47) | (22.18) | (5.19) | 5.51 | — | — | — | (3.69) |
P/FCF ratio |
0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 |
P/Operating CF |
(4.62) | — | (22.62) | (19.32) | (5.79) | (17.75) | — | — | — | (22.39) |
Beneish M-Score |
— | — | — | 1,568.55 | (0.92) | — | — | — | — | — |
P/B ratio |
0.62 | — | 4.48 | 3.56 | 0.91 | 1.34 | — | — | — | 3.78 |
Price to Tangible BV |
0.62 | — | 4.48 | 3.56 | 0.91 | 1.34 | — | — | — | 3.78 |
EV/Sales |
(291.15) | — | 729.25 | 586.10 | (13.15) | 3.61 | — | — | — | 2.66 |
EV/EBITDA |
0.32 | — | 0.00 | 0.00 | 0.24 | 0.00 | — | — | — | 0.00 |
EV/Operating CF |
0.73 | — | (3.75) | (2.26) | 0.27 | (0.94) | — | — | — | (3.14) |
EV/FCF |
0.72 | — | (3.75) | (2.26) | 0.27 | (0.94) | — | — | — | (3.06) |
Quick Ratio |
6.41 | 3.62 | 6.11 | 5.41 | 7.63 | 11.03 | 14.46 | 24.00 | 15.17 | 6.36 |
Current Ratio |
6.56 | 3.62 | 6.41 | 5.71 | 7.68 | 11.13 | 14.84 | 24.22 | 15.56 | 6.40 |
Net Debt/EBITDA |
1.40 | (0.16) | 1.07 | 1.01 | 1.41 | 2.64 | 2.54 | 4.10 | 3.68 | 1.26 |
Debt/Assets |
0.00% | 105.24% | 0.00% | 0.00% | 0.97% | 1.34% | 1.68% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | (2.42) | 0.00 | 0.00 | 0.01 | 0.02 | 0.02 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.08 | 0.00 | 0.00 | 0.00 | 0.01 | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.54 | 0.82 | 0.95 | 1.00 | 0.91 | 0.77 | 0.90 | 0.90 | 0.89 | 0.93 |
Capex/Depreciation |
(10.94) | 0.57 | (0.14) | (0.41) | (0.06) | (0.25) | (0.52) | (0.46) | (1.12) | (3.70) |
Interest Coverage |
(69.85) | (20.18) | — | (66.34) | (3,204.40) | (106.76) | (17.55) | (15.94) | (52.11) | (308.05) |
| (145.42%) | (330.31%) | (90.72%) | (74.98%) | (60.46%) | (36.14%) | (32.19%) | (29.69%) | (42.94%) | (83.96%) | |
| (96.73%) | (93.61%) | (75.98%) | (63.89%) | (53.48%) | (32.84%) | (30.25%) | (28.11%) | (38.93%) | (70.03%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(66.25%) | (150.37%) | (99.85%) | (110.96%) | (79.95%) | (40.35%) | (37.99%) | (23.61%) | (27.70%) | (90.26%) |
Average Days of Receivables |
605.87 | — | 0.00 | 700.80 | 0.41 | 0.08 | 0.00 | 0.00 | 0.00 | 5,301.38 |
Research and Development Expense of Revenue |
1,273.39% | 0.00% | 200,717.00% | 37,854.53% | 4,094.81% | 442.09% | 0.00% | 0.00% | 0.00% | 125,847.57% |
Selling, General and Administrative Expense of Revenue |
234.14% | 0.00% | 192,136.00% | 25,449.87% | 1,475.72% | 164.75% | 0.00% | 0.00% | 0.00% | 46,757.84% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
122.65% | 0.00% | 35,605.00% | 5,143.47% | 524.86% | 67.91% | 0.00% | 0.00% | 0.00% | 16,025.95% |
Graham Net Nets |
1.61 | — | 0.21 | 0.27 | 1.05 | 0.72 | — | — | — | 0.25 |
Graham Number |
0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 |
Earnings Yield |
(251.53%) | — | (21.32%) | (30.24%) | (85.42%) | (29.52%) | — | — | — | (24.08%) |
Free Cash Flow Yield |
(58.64%) | — | (20.26%) | (30.45%) | (77.62%) | (22.87%) | — | — | — | (22.83%) |
Revenue per Share |
1.04 | 0.00 | 0.02 | 0.14 | 2.25 | 22.23 | 0.00 | 0.00 | 0.00 | 0.09 |
Operating CF per Share |
(6.87) | (48.23) | (55.07) | (88.44) | (111.74) | (85.83) | (120.17) | (105.56) | (101.25) | (139.85) |
Capex per Share |
(0.09) | 0.03 | (0.03) | (0.16) | (0.03) | (0.15) | (0.33) | (0.31) | (1.00) | (3.31) |
Free Cash Flow per Share |
(6.96) | (48.20) | (55.10) | (88.60) | (111.77) | (85.98) | (120.50) | (105.86) | (102.25) | (143.16) |
Cash per Share |
20.47 | 53.92 | 65.98 | 91.13 | 175.42 | 299.73 | 365.70 | 511.37 | 421.51 | 188.34 |
Shareholders Equity per Share |
19.49 | (24.01) | 60.65 | 81.72 | 158.61 | 280.45 | 356.45 | 500.52 | 407.15 | 166.04 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
19.49 | (24.01) | 60.65 | 81.72 | 158.61 | 280.45 | 356.45 | 500.52 | 407.15 | 166.04 |
Free Cash Flow |
(72.45) | (31.08) | (34.90) | (46.54) | (57.50) | (39.31) | (52.13) | (43.46) | (30.06) | (30.44) |
Working Capital |
200.58 | 25.19 | 36.96 | 41.83 | 78.96 | 125.84 | 151.58 | 203.51 | 119.04 | 34.19 |
Capital Expenditures |
(0.92) | 0.02 | (0.02) | (0.08) | (0.01) | (0.07) | (0.14) | (0.13) | (0.29) | (0.70) |
Net Current Asset Value |
199.37 | (16.29) | 36.89 | 41.83 | 78.05 | 123.66 | 148.76 | 202.89 | 118.34 | 33.43 |
EV/EBIT |
0.34 | — | 0.00 | 0.00 | 0.24 | 0.00 | — | — | — | 0.00 |
Capex to Sales |
0.08 | 0.00 | 2.14 | 1.12 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 38.06 |
Price to Operating Income |
0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.10 | 0.00 | 0.00 | 0.85 | 0.72 | 0.44 | 0.34 | 0.29 | 0.24 | 0.18 |
Cash ROIC |
(17.41%) | (54.74%) | (43.51%) | (51.26%) | (33.28%) | (14.71%) | (16.54%) | (10.46%) | (12.34%) | (40.40%) |
Accounts Receivable Turnover |
1.20 | — | 0.00 | 1.03 | 682.24 | 108.06 | 0.00 | 0.00 | 0.00 | 0.10 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — |
Average Receivables |
9.07 | — | — | 0.07 | 0.00 | 0.09 | 0.30 | 0.26 | 0.19 | 0.19 |
Average Payables |
8.73 | 4.10 | 0.92 | 1.54 | 2.10 | 1.76 | 2.05 | 2.66 | 2.11 | 1.06 |
Average Assets |
137.96 | 40.47 | 48.56 | 73.08 | 118.59 | 155.40 | 191.40 | 171.71 | 85.49 | 45.43 |
Average Common Equity |
91.77 | 11.47 | 40.67 | 62.27 | 104.91 | 141.21 | 179.83 | 162.58 | 77.50 | 37.89 |
Columns are period end dates · fundamentals updated 26 Oct 2026